AstraZeneca PLC (NASDAQ:AZN) Shares Sold by LVW Advisors LLC

LVW Advisors LLC trimmed its position in AstraZeneca PLC (NASDAQ:AZN) by 8.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,962 shares of the company’s stock after selling 1,564 shares during the period. LVW Advisors LLC’s holdings in AstraZeneca were worth $1,046,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after acquiring an additional 133 shares during the last quarter. Crumly & Associates Inc. lifted its position in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after acquiring an additional 143 shares during the last quarter. Veery Capital LLC lifted its position in shares of AstraZeneca by 4.7% during the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock valued at $230,000 after acquiring an additional 157 shares during the last quarter. Harbour Investments Inc. lifted its position in shares of AstraZeneca by 1.9% during the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after acquiring an additional 160 shares during the last quarter. Finally, Smith Salley Wealth Management lifted its position in shares of AstraZeneca by 1.0% during the 3rd quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after acquiring an additional 162 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Trading Down 0.5 %

NASDAQ AZN opened at $66.60 on Monday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $206.50 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. The firm’s fifty day simple moving average is $66.11 and its 200-day simple moving average is $74.48.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the business posted $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.